We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Antibody May Improve Survival in Recurrent Glioblastomas

Jul 1, 2001
Volume: 
10
Issue: 
7

SAN FRANCISCO—In a phase II trial of the chimeric monoclonal
antibody 131I-chTNT-1/B (Cotara), survival in 22 patients with
recurrent glioblastoma multiforme was significantly increased, compared with
that of historical controls.

Expected progression-free survival in patients with this
disease in first relapse is usually no more than 8 to 12 weeks. Despite
inclusion of heavily pretreated patients with multiple relapses, the Cotara
trial showed a median time to progression of 14 weeks and median survival of 27
weeks in patients with recurrent glioblastoma multiforme.

Sunil J. Patel, MD, associate professor of neurosurgery,
Medical University of South Carolina, Charleston, reported the results at the
37th Annual Meeting of the American Society of Clinical Oncology (ASCO), held
in San Francisco.

"The drug has good binding to the tumor, and it can be
given with minimal toxicity," Dr. Patel said. "We’re seeing very
large distribution of the drug into the tumor, and our preliminary phase II
data indicate that there is some efficacy. We haven’t cured anyone, but we’ve
certainly improved survival."

The agent targets a complex of double-stranded DNA and histones
found in necrotic tissue associated with cancer. Radioactive iodine attached to
the antibody kills the tumor.

"By targeting the radiation to regions of the tumor, we
avoid systemic toxicity," Dr. Patel said, "and also significantly
minimize brain toxicity, which can occur with external beam radiation."

The drug, being developed by Peregrine Pharmaceuticals, Inc. (Tustin,
Calif), which sponsored the study, is delivered directly into the brain via two
catheters placed stereotactically into different parts of the tumor. The drug
is infused over 24 to 48 hours in the hospital.

"Like an IV infusion, the tube stays in the head. Patient
can walk around the hospital with the IV pump; then the catheter is taken out
and they go home," Dr. Patel explained.

Dr. Patel and his colleagues at Temple University, the
University of Utah, Carolina Neurosurgery & Spine, and the Barrow
Neurological Institute are getting ready to launch a phase III trial of Cotara
in brain tumor patients.

"It is certainly a promising drug," he said,
"but we still have to show a large number of patients improving. We still
need to treat a few more patients who have been newly diagnosed with the tumor
who have not had previous therapy. That would be an ideal group of
patients."

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.